logo-loader

AB InBev may struggle to thrive in Africa, Deutsche Bank suggests

Africa is not Brazil, nor Mexico. It’s a continent, not a country, so the single market organizational model may not work

Budweiser
The retained SABMiller businesses have higher margins

European banking giant Deutsche Bank is lukewarm on brewing behemoth Anheuser-Busch InBev (NYSE:BUD), following the release of the reference base for the ongoing business.

The Belgian brewing firm has now either got shot of all the assets it agreed to sell in order to get the authorities to agree to its takeover of rival SABMiller, or it has agreed the sales.

“The remaining SABMiller stub has higher margins than ABInBev, putting into question some of the synergy targets released before ABInBev even received the keys,” according to the Deutsche team.

AB InBev is targeting US$1.9bn of cost synergies following the takeover.

“Having ultimately paid a 28x EV/EBITDA [enterprise value/underlying earnings] multiple for what remains of SABMiller, the usual plan is for cost cutting and ‘dream’ incentives to get the troops into line. Looking at the numbers and the company actions thus far, we remain skeptical,” Deutsche said.

What Deutsche called the “bevy” of consultants used in previous AB InBev deals have set bold key performance indicators, but in the German bank’s view with few guide rails to ensure sustainability beyond year one.

“Despite contrary multiple pronouncements by the company, Africa is not Brazil, nor Mexico. It’s a continent, not a country; unlike the Anheuser-Busch and Modelo deals, we question the applicability of the single market organizational model,” the bank revealed.

There also looks to be little incentive for those former SABMiller employees with the knowledge to stick around and execute.

According to Deutsche, permanent roles, continuity contracts and the like have been offered, but competitors, both globally and locally, have picked off the talent, both in beer and spirits.

The bank rates the shares as no more than a ‘hold’.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Arcadia Biosciences makes major progress on its hemp venture...

Arcadia Biosciences Inc (NASDAQ:RKDA) CEO Raj Ketkar tells Proactive the California-based company expects to “significantly scale revenues in 2020” as it reported financial and business results for the second quarter and first half of 2019. Ketkar says the agricultural innovation company made...

1 day, 20 hours ago

2 min read